store at -20°C
Tocilizumab [375823-41-9]
Cat# T9911-2mg
Size : 2mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Tocilizumab
Catalog No. T9911 CAS 375823-41-9
Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Tocilizumab, CAS 375823-41-9
| Description | Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor |
| Cell Research | Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function. Concentrations: 5 μg/ml. Incubation Time: 72 h. Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis. Cells:HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma) |
| Molecular Weight | 148 kDa |
| CAS No. | 375823-41-9 |
Storage
References and Literature
1. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70 2. Kim NH, et al. Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells. Oncol Lett. 2015 May;9(5):2283-2288. 3. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.
Citations
1. Meng H, Fan L, Zhang C J, et al. Synthetic VSMCs Induce BBB Disruption Mediated by MYPT1 in Ischemic Stroke. iScience. 2021: 103047. 2. Nicholson M W, Huang C Y, Wang J Y, et al. Cardio-and Neurotoxicity of Selected Anti-COVID-19 Drugs. Pharmaceuticals. 2022, 15(6): 765 3. Stauber T, Moschini G, Hussien A A, et al.IL-6 SIGNALING EXACERBATES HALLMARKS OF CHRONIC TENDON DISEASE BY STIMULATING PROGENITOR PROLIFERATION & MIGRATION TO DAMAGE.bioRxiv.2023: 2023.02. 13.528273.
Related Products
Related compounds with same targets
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Keywords
Tocilizumab 375823-41-9 Immunology/Inflammation Interleukin COVID-19 IL-6R Anti-Human IL6R, Humanized Antibody rheumatoid respiratory failure antibody Interleukin Related coronavirus disease arthritis inhibit dyspnoea Neutralizing Inhibitor inhibitor